

## Special Issue

# Advances in Genitourinary Tumour Genomics and Immunotherapy

### Message from the Guest Editor

Genomics and immunotherapy play pivotal roles in modern approaches to treating genitourinary tumors, leveraging the immune system to combat cancer and offering tailored treatments based on genetic profiles. Immunotherapy has emerged as a critical tool, providing new perspectives and therapeutic avenues. Meanwhile, genomic data are instrumental in identifying biomarkers that forecast treatment responses and overall prognoses. Specific genetic mutations have also paved the way for targeted therapies, guiding decisions in immunotherapy. Ongoing research endeavors seek to refine these methodologies further, aiming to enhance outcomes for patients grappling with these complex cancers. **Aim and scope:** To disseminate high quality research on immunotherapy and genomics in the field of genitourinary cancer

---

### Guest Editor

Prof. Dr. Leonardo O. Reis

1. UroScience, School of Medical Sciences, State University of Campinas, Campinas, São Paulo, Brazil
2. ImmunOncology, Pontifical Catholic University of Campinas, Campinas, São Paulo, Brazil
3. National Institute of Science, Technology and Innovation in Genitourinary Cancer, Campinas, São Paulo, Brazil

---

### Deadline for manuscript submissions

closed (30 December 2024)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/si/208788](https://mdpi.com/si/208788)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Experimental Cancer Therapeutics, The University of Alabama at  
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-  
2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))